One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1158/1538-7445.sabcs21-pd13-03
Copy DOI
Export
Save
Share
Cite Journal: Cancer Research |  Publication Date: Feb 15, 2022 |
 Citations: 1 |
Affiliation: Yale University, University of Pennsylvania, Northwest Medical Specialties, Tennessee Oncology, Sarah Cannon, Florida Cancer Specialists & Research Institute, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Tris Pharma (United States), UCSF Helen Diller Family Comprehensive Cancer Center, Massachusetts General Hospital, Northside Hospital
Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
